Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - hexaminolevulinate hydrochloride - pdr+solv/soln/intravesical use - 85 milligram(s) - other diagnostic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen limited - macrogol 4000 - powder for oral solution - 10 grams - osmotically acting laxatives

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - lanreotide - powder and solvent for suspension for injection - 30 milligram(s) - somatostatin and analogues; lanreotide

Malta - English - Medicines Authority

ipsen m.e.p.e ag. dimitriou 63 alimos, 17456 athens, greece - hexaminolevulinate - powder and solvent for solution for intravesical use - hexaminolevulinate 85 mg - diagnostic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - triptorelin - powder and solvent for prolonged-release suspension for injection - 11.25 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 31 mg (equivalent: triptorelin, qty 22.5 mg) - suspension, powder for - excipient ingredients: polyglactin; carmellose sodium; polysorbate 80; mannitol - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.,diphereline 22.5mg 6 month formulation only:,diphereline 22.5 mg is indicated for the treatment of children 2 years and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 19.32 mg - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - triptorelin acetate - powder and solvent for suspension for injection - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - lanreotide acetate - powder and solvent for suspension for injection - 30mg